Obtaining funds: what to know, what to do. Esper G. Kallas, M.D., Ph.D.

Similar documents
HIV vaccine research and development

Planning, Priority Setting, and Budget Development for NIH AIDS Research

17-18 March 2011, São Paulo, Brazil. Blended Workshop Evaluation

Questions and answers: HVTN 084 vaccine trial

Outline. Mission. NCCIH Research Priorities HSR Community Conference September 11, National Center for Complementary and Integrative Health

Disclaimer. The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be

Excellence in Trial Management

Pediatric Randomized of Early vs Deferred Initiation in Cambodia and Thailand

Fall 2018 Research Training Program Agenda. S E S SI ON 1, Tuesday, S eptember 11, 2018

Building Long-term Capacity for HIV/AIDS in Africa: S-S and Regional Strategies

Office of Clinical Research Annual Report 2017 July 1, June 30, 2017

Evaluations. Dementia Update: A New National Plan for Alzheimer s Disease Research, Care and Services. Disclosure Statements.

The Financial Value of STTR for Non-Profit Research

UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM. A5272 Version 2.0, 5/19/11: Oral HPV Shedding and Oral Warts After Initiation of Antiretroviral Therapy

Report and Action Plan

Dengue: A disease burden in Sri Lanka A Complex Phase III Vaccine Trial

FUNDERS UPDATE- BMGF. Third HIV Env Manufacturing Workshop Sponsored by DAIDS-NIAID-NIH and the HIV Global Vaccine Enterprise July 20-21, 2017

TITLE: Obtaining Informed Consent of Non-English Speakers SOP #: CON-101 (formerly SM-507) Page: 1 of 7 Effective Date: 1/14/2016

University of Prince Edward Island PANDEMIC PREPAREDNESS PLAN. October 7, 2009

FINANCIAL MANAGEMENT ASSESSMENT: UPDATED RISK ASSESSMENT

Planned Vaccine Trials to Follow-up on RV 144. Merlin Robb, MD Deputy Director for Clinical Research MHRP

The Economic and Social Council, Recalling the United Nations Millennium Declaration13 and the 2005 World Summit Outcome, 1

Position Specification

CRS Report for Congress

Ryan White HIV/AIDS Part C Capacity Development Program Pre-Application Technical Assistance Conference Call HRSA February 12, 2014

On behalf of the Infectious Diseases Society of America (IDSA), I am pleased to provide

REVISIONS: Strategies to Achieve the Healthy People 2020 Annual Goal of 90% Influenza Vaccination Coverage for Health Care Personnel

Clinical Research Unit Charter

Understanding Clinical Trials

Practice Direction Standard of Practice # 5: Administration of Drugs including Vaccines

SAMHSA: A Public Health Agency

EPA REGULATORY UPDATE

Specific Accreditation Guidance OECD GLP

MASSACHUSETTS COMMISSION ON DEAF AND HARD OF HEARING Annual Family Support Plan Report FY 07

LETTER OF AMENDMENT #2 TO: MTN-036/IPM 047. A Phase 1, Randomized Pharmacokinetics and Safety Study of Extended Duration Dapivirine Vaginal Rings

Challenges in HIV Vaccine phase III Community-based Trial in Thailand. AIDS Vaccine 2007 Conference,

PEDIATRICS. THE POWER OFx. Experts. Experienc e. Execution. Conducting Pediatric Studies Presents Great Challenges. Experts: Experience: Execution:

ATTUD APPLICATION FORM FOR WEBSITE LISTING (PHASE 1): TOBACCO TREATMENT SPECIALIST (TTS) TRAINING PROGRAM PROGRAM INFORMATION & OVERVIEW

HVTN 505 Study HIV Vaccine Candidate Not Effective

Developing a National Program: Brazil Case Study: Vera Luiza da Costa e Silva, MD, MBA, PhD

New Horizons for Vaccine R&D&I in Europe

Massachusetts Medicaid pediatric high-risk asthma bundled payment pilot

MARCH OF DIMES: FISCAL YEAR 2019 FEDERAL FUNDING PRIORITIES

PROMOTING AN EFFECTIVE MEDICAL COUNTERMEASURES ENTERPRISE


BRP update from the NCI Acting Director

Oncology Treatment Network Structure in Russia and its Impact on the Success of Oncology Clinical Studies

Ebola Prevention Vaccine Evaluation in Sierra Leone

Weekly NIH Funding Opportunities and Notices NIH Guide for Grants and Contracts Table of Contents (TOC)

Cancer Control in Developing Countries

Early Intervention and Diagnosis in Paediatric Neurodevelopment Defects in Brazil, November, Rio de Janeiro, Brazil

Local Government Pandemic Influenza Planning. Mac McClendon, Chief / Office of Public Health Preparedness Emergency Management Coordinator

IRB Approved: 09-Jan-2015 To: 08-Jan-2016

December 14, Letter of Amendment 1 Version 2.0 HVTN 704/HPTN 085

Update of The National Vaccine Plan

Centers for Disease Control and Prevention (CDC) FY 2009 Budget Request Summary

Community Health Workers (CHWs) in HIV Services: Insights from Virginia. November 16, 2017

Abt Associates Inc. Immunization and Health Services Research Helping our clients address critical health issues around the world

Request for Letters of Intent. International Development of H5N1 Influenza Vaccines

November 13, 2009 Licensure, Evaluation, and Adverse Event Monitoring of the 2009 H1N1 Influenza Vaccine By Matthew Watson and Jennifer Nuzzo

PEDIATRICS. THE POWER OFx. Experts. Experienc e. Execution. Conducting Pediatric Studies Presents Great Challenges. Experts: Experience: Execution:

Letter from the CEO. Dear Friends of IAVI,

Towards a Sustainable Global Infrastructure for Medical Countermeasures

Welcome to presentation By Sanjay Punjabi Lead Auditor for ISO 9001, ISO 14001, OHSAS & BS 7799

Informed Consent Procedures and Writing Informed Consent Forms


RESOLUTION OF THE STATE GREAT KHURAL OF MONGOLIA. 11 October 2002 No: 68 Ulaanbaatar. Adoption of the Government Policy on Drugs

STRADA : Strategy to improve screening of infectious diseases, tuberculosis, HIV, HBV and HCV in the migrant population in France

Outcomes & Opportunities through Collaborating in Clinical Trials

Parkinson s Research Program

Hepatitis B Foundation (HBF) Meetings with National Institutes for Health (NIH) On Research Opportunities For Finding A Cure For HBV March 12, 2018

CPRIT Overview. Cancer Centers Administrators Forum April 4, 2016

NCIC CTG Overview and Opportunities. Ralph Meyer Director, NCIC CTG

Standard Operating Procedures (SOP) Research and Development Office

MIAMI CHILDREN S HOSPITAL POLICY AND PROCEDURE

Approach to the Ethical Review

Tuberous Sclerosis Australia Strategic Plan

Financial Resources for HIV: PEPFAR s Contributions to the Global Scale-up of Treatment

2010 Mecklenburg County Health Department Community Report Appointments: General Information:

Evaluation of prognostic factors and survival among patients with osteosarcoma attended at a philanthropic hospital in Teresina, Piauí, Brazil

National Plan to Address Alzheimer s Disease

Statement Of. The National Association of Chain Drug Stores. For. U.S. Senate Finance Committee. Hearing on:

FY 2015 OMNIBUS SPENDING BILL

FALL 2018 SCHEDULE Monday, October 15 th 9 A.M. 6 P.M. Tuition - $350

Stephen C. Joseph, M.D., M.P.H.

Antonio M. Martinez. Career Experience. Research Experience. 601 S Mesa Hills #1122 El Paso, TX, (915)

Program Priorities 2018

Developing with. Faith

Hospital Geral de Nova Iguaçu HGNI (HIV Family Care Center) José Henrique Pilotto, MD PHD Principal investigator and CRS leader - Site 5097

IRB Approval From: 3/8/2010 To: 10/28/2010

VA Funding Opportunities & Research Resources

Increasing Adult Immunization Rates in the US Through Data and Quality: A Roadmap

Western Institutional Review Board Located in Olympia, Washington Privately funded review board WIRB is registered with FDA/OHRP.

Public Health Emergencies: Mass Dispensing in the Community

USU Center for Neuroscience and Regenerative Medicine (CNRM)

DEVELOPMENTS IN THE CLINICAL TRIALS ENVIRONMENT Two Initiatives February 27, 2014

Pandemic Influenza: Appropriations for Public Health Preparedness and Response

PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM

California HIV/AIDS Research Program

Welcome to. The Fundamentals of International Clinical Research Workshop. Stevenson, Washington

Transcription:

Obtaining funds: what to know, what to do Esper G. Kallas, M.D., Ph.D.

Funding sources Local funding agencies International funding agencies Pharmaceutical and biotech industries

Funding sources Brazil Brazilian Reais 1.400.000.000 1.200.000.000 1.000.000.000 800.000.000 600.000.000 400.000.000 CNPq FAPESP Linear (CNPq) Linear (FAPESP) 200.000.000 0 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 Year Source: www.fapesp.br & www.cnpq.br

Funding source NIH Billions of Dollars $30 $25 $20 $15 $10 $5 $13.7 $15.6 $17.8 $20.5 $23.3 $27.1 $28.0 $28.6 $28.6 $28.6 $0 FY 1998 FY 1999 FY 2000 FY 2001 FY 2002 FY 2003 FY 2004 FY 2005 FY 2006 FY 2007 DOUBLING Source: www.nih.gov

Big Pharma 1000 800 Number of reports 600 400 200 0 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 Year Source: www.anvisa.gov.br

An overall general principle Clinical Applications Translational Research Basic Research and Technology Development

Institutional strategic view Discussion of strategies Fostering research in different levels Clinical application Translational research R&D Seed money Incentives for investigators Seek funding opportunities continuously Well organized structure

Well organized structure Infrastructure Administrative Finances Personnel Grant specialists Regulatory affairs Secretary

Experience background 1994 Started conducting Pharma-sponsored clinical research 1999 Started obtaining institutional funds Started applying for NIH grants in 2002 First Phase I trial in 2003, Merck HIV vaccine candidate HIV vaccine candidate study (STEP trial, Phase IIb) First NIH award (foreign component) in 2006 (R01 with UCSF, Dr. Douglas Nixon) U01 award: Sao Paulo Clinical Trials Unit at UNIFESP and CRT-DST/Aids 2007: R21 and R01 awards (as foreign component) 2008: Clinical Research Site at USP

Clinial Trials Unit Principal Investigator Esper Kallas Executive Committee Co-Principal Investigator Artur Kalichman CTU Administrator Maria Candida Dantas Finance Administrator Maria Aparecida Moreira Clinical Coordinator Ricardo Palacios NIH relationship Reporting Legal issues Accounting Accounts Payable Accounts Receivable Controlling Payroll Community Advisory Board Community Education Coord. Gabriela Calazans FAP-UNIFESP HVTU Vila Mariana Artur Kalichman (CRS HVTN) Community education Recruitment/retention Sirlene Caminada Ethics Regulatory issues Data management Volunteer safety Laboratory Management Helena Tomiyama Product Management Gustavo Mizuno

Clinical Research Sites HVTU Vila Mariana Artur Kalichman (CRS HVTN) Clinical specimens Clinical Laboratory CRT-DST/AIDS Routine & protocol tests CTU core Immunology Laboratories UNIFESP Imune assays Sample repository Shipment

Site expansion: USP University of Sao Paulo Division of Allergy of Infectious Diseases LIM-60 Laboratory Clinical Research Center

Other ongoing projects DAIDS (NIAID) sponsored trials Pharma sponsored studies

Structure Division PI Clinical Research Site Subinvestigators Study coordinator Administrator Nursing Pharmacy Admin Study nurse Pharmacists Receptionist Regulatory affairs Dada coordinator Recruitment and retention Community educator Assistant Recruiters Counselers

Laboratory Samples Central Laboratory LIM-60 Safety Repository Immune assays T cell counts Extended phenotype Immune function Molecular Biology

Clinical requirements Good clinical practices Training SOPs Documentation

Laboratories requirements Good laboratory practices ANVISA 17025 (includes ISO 9001) InMetro Training NIH compliance Safety: CAP proficiency GLP Guidelines Pharma compliance

Complexo Hospital das Clínicas 1 Instituto Central 2 Instituto do Coração 2 3 Instituto de Radiologia 4 Instituto de Ortopedia e 1 Traumatologia 5 Prédio da Administração 6 Instituto de Psiquiatria 3 4 5 6 7 Instituto da Criança 8 Laboratórios de Investigação Médica 9 Divisão de Medicina de Reabilitação 10 Hospital Auxiliar de Cotoxó 11 Hospital Auxiliar de Suzano 12 Hospital Estadual de Sapopemba 22/10/07 Andréa Macorin Pinheiro

Central Institute 22/10/07 Andréa Macorin Pinheiro

Outpatient clinic building 22/10/07 Andréa Macorin Pinheiro

Centro de Pesquisas Clínicas ICHC FMUSP 22/10/07 Andréa Macorin Pinheiro

CPC Main hallway 22/10/07 Andréa Macorin Pinheiro

CPC Medical office 22/10/07 Andréa Macorin Pinheiro

CPC Monitoring room 22/10/07 Andréa Macorin Pinheiro

CPC Nursing room 22/10/07 Andréa Macorin Pinheiro

CPC Testing room 22/10/07 Andréa Macorin Pinheiro

CPC Testing room 22/10/07 Andréa Macorin Pinheiro

CPC - Pharmacy 22/10/07 Andréa Macorin Pinheiro

CPC - Pharmacy 22/10/07 Andréa Macorin Pinheiro

CPC - Pharmacy 22/10/07 Andréa Macorin Pinheiro

Identificação Protocolos 22/10/07 Andréa Macorin Pinheiro

The institution needs to be prepared Federal Wide Assurance (FWA) number Institutional Review Board (IRB) number Institutional registration at grants.gov Data Universal Number System (DUNS) number Central Contractor Registry (CCR) number Cage Code (Commercial and Government Entity Code) In Brazil: A NATO number, provided by the Navy!! era Commons registration

Site activation process Protocol approval Site evaluation by the NIH & CRO Compliance Quality management plan SOPs Training Pharmacy plan Community Advisory Board Laboratories NIH Laboratory Branch evaluation CRO evaluation Activation NIH & CRO

Regulatory process Translation (back translation may by required) In the US (if you are a foreign component) IRB submission in the primary institution In Brazil IRB and CONEP CNPq CIBio and CTNBio (when required) ANVISA (when required)

Time lag for regulatory approval Document portfolio: 2 weeks to 1 month IRB approval: 1 to 2 months CONEP approval: 3 to 4 months Anvisa approval: 1 month Total time: around 6 months.

Conclusions Brazilian funding agencies are investing more Funding opportunities in international agencies are within reach Clinical research in the country has increased Institutional preparedness and support are essential

Conclusions Conduction of clinical trials can be done in Brazil, under strict GCP and GLP standards Approval process can take a long time However, the Brazilian participation is usually successful and fast

University of São Paulo Site Clinical coordinator: Ricardo Palacios Administrator: Maria Candida Dantas Regulatory affairs: Zelinda Nakagawa, Issler Silva Investigators: Mariana Sauer, Fábio Leal, João Miraglia Nurses: Laís Magalhães, Maria Emília Campos Pharmacists: Lígia Correa, Maria Teresa Giret, Andréa Pinheiro Community educator: Ricardo Gambôa Counsellors: Flávia Penacchin, Daniel Bertevello Dada management: Ricardo Russo, Angela Lima Laboratory: Helena Tomiyama, Leandro Tarosso, Fernanda Bruno Team: 24 pessoas Laboratório Central: Marcelo Burattini Centro de Pesquisa Clínica: Décio Mion

Bob Grant, Uganda 1992 Merle Sande 1939-2007 22/10/07 Andréa Macorin Pinheiro